Výsledky vyhledávání - "Nicole Cichanowitz"

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

Autor: Kristian Reich, Nicole Cichanowitz, Kim Papp, Andrew Blauvelt, Melinda Gooderham, C. La Rosa, Alexa B. Kimball, Qing Li

Publikováno v: The British Journal of Dermatology

Summary Background Chronic psoriasis may require medication adjustments over time. Objectives To evaluate the efficacy/safety of tildrakizumab in subgroups from the reSURFACE studies (N = 1862) that received continuous dosing, higher/lower dosing, tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dfa0cc2898e146fd304bf10dbcdad31
https://pubmed.ncbi.nlm.nih.gov/31487406

Zobrazit plný text záznamu

Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28

Autor: Alexa B. Kimball, Kristian Reich, Melinda Gooderham, S. K. Tyring, Kim Papp, Stuart A. Green, C. La Rosa, Diamant Thaçi, Rodney Sinclair, Qing Li, Andrew Blauvelt, Nicole Cichanowitz

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV. 33(6)

BACKGROUND: Efficacy of tildrakizumab for plaque psoriasis was demonstrated in randomized, placebo-controlled trials. OBJECTIVE: To consolidate tildrakizumab efficacy results by pooling data. METHODS: Data (N = 2081) from tildrakizumab 100 mg, tildra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf28def84391fa7cc8a71211f327d6c
https://pubmed.ncbi.nlm.nih.gov/30838709

Zobrazit plný text záznamu

THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials

Autor: Alan M. Mendelsohn, Howard Sofen, Melinda Gooderham, Nicole Cichanowitz, Boni E. Elewski, David M. Pariser, C. La Rosa, Qing Li

Publikováno v: THURSDAY, 14 JUNE 2018.

Background Tildrakizumab, is a high-affinity, humanised, anti–IL-23p19 monoclonal antibody for the treatment of chronic plaque psoriasis. Objectives Here, we evaluated gastrointestinal (GI) adverse events (AE) and, specifically, cases of inflammato

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8faf03e96805706a13267150b773ff6a
https://doi.org/10.1136/annrheumdis-2018-eular.6782

Zobrazit plný text záznamu

AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders

Autor: C. La Rosa, Jeffrey J. Crowley, J. Parno, Nicole Cichanowitz, Chih-Ho Hong, Kim Papp, Qing Li, Alan M. Mendelsohn

Publikováno v: Psoriatic arthritis.

Background Etanercept (ETN) is an anti–tumour necrosis factor (TNF) medication that was among the first biologics approved for psoriasis. Additional medications have been developed or are in development for psoriasis, and patients who do not adequa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c699626e1f29f53da87b8f5608d026f
https://doi.org/10.1136/annrheumdis-2018-eular.6758

Zobrazit plný text záznamu

SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis

Autor: Qing Li, Jeffrey J. Crowley, C. Leonardi, Alan Menter, Alan M. Mendelsohn, S. Sturgill-Koszycki, Nicole Cichanowitz, C. La Rosa

Publikováno v: Saturday, 16 JUNE 2018.

Background Risk of infections is a concern with cytokine inhibitor treatments. Objectives This analysis assessed infections during phase 2 and 3 trials of tildrakizumab (TIL), a high-affinity, humanised, immunoglobulin G1/κ monoclonal antibody again

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19520abde369f1d1cb9fb7c6645b5c09
https://doi.org/10.1136/annrheumdis-2018-eular.6730

Zobrazit plný text záznamu

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials

Autor: Stuart A. Green, Nicole Cichanowitz, Melinda Gooderham, Kristian Reich, Rodney Sinclair, C. La Rosa, Stephen K. Tyring, Alexa B. Kimball, Andrew Blauvelt, Kim Papp, Qing Li, Diamant Thaçi

Publikováno v: The British journal of dermatology. 179(3)

BACKGROUND: Short-term interleukin-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears to be well tolerated. OBJECTIVES: Safety and tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from thre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd6ca9dd9bac958676ba2fb17c63616
https://pubmed.ncbi.nlm.nih.gov/30222877

Zobrazit plný text záznamu

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Autor: Kenneth Liu, Anish Mehta, Diamant Thaçi, Rodney Sinclair, Qing Li, Carmen La Rosa, Kristine Nograles, Kristian Reich, Stuart A. Green, Stephen K. Tyring, Kim A. Papp, Alexa B. Kimball, Andrew Blauvelt, Nicole Cichanowitz

Publikováno v: Lancet (London, England). 390(10091)

Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis. Previous research suggested clinical improvement with inhibition of interleukin 23

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b01dde029099a53188f1f23d82f18a81
https://pubmed.ncbi.nlm.nih.gov/28721878

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání